A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
| Заболевание | Colitis, Ulcerative |
|---|---|
| Фаза | Фаза 3 |
| Спонсор | Janssen Research & Development, LLC |
| Статус | Идёт, набор закрыт |
| Участники | 84 участн. |
| Вмешательство | Golimumab, Infliximab |
| Дата начала | 29.10.2018 |
| Дата завершения | 21.11.2023 |
| Публикация результатов | 14.11.2025 |
Кратко
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC). In addition, the safety profile of golimumab, in pediatric participants with moderately to severely active UC will be assessed.
Percentage of Participants With Clinical Remission at Week 6 as Assessed by the Mayo Score
| Group 1: Golimumab | 31.9 Percentage of participants |
|---|
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University
- ENhanced Recovery in CHildren Undergoing Surgery — Northwestern University